Case Study

Building an AI-Enabled Services Growth Strategy

A national specialty provider network engaged CWH Advisors to identify where AI could accelerate growth across its pharmaceutical services business. CWH helped leadership prioritize high-value opportunities, quantify the business case, evaluate technology partners, and define phased pathways from strategy to implementation.

Client Pain Points

  • Sought new growth opportunities by expanding pharmaceutical services through AI-enabled offerings with meaningful commercial potential.
  • Faced capacity constraints from manual workflows across clinical investigations and market research that limited scalability.
  • Needed greater clarity on which AI opportunities could balance business value, market demand, workflow fit, compliance requirements, and operational readiness.
  • Required a consistent decision framework for comparing opportunities and technology partners against economics, stakeholder needs, implementation feasibility, and time to value.

CWH Solutions

  • Assessed and prioritized AI-enabled opportunities across clinical investigations, market research, and advisory services based on strategic fit, commercial potential, and implementation feasibility.
  • Built financial business cases linking demand, economics, cycle-time improvements, operational assumptions, provider participation, and expected value creation.
  • Defined business, technical, compliance, and adoption requirements and evaluated more than 30 AI technology providers through market research, vendor interviews, demonstrations, and structured scorecards.
  • Developed phased implementation roadmaps outlining preferred technology partners, pilot strategies, partnership considerations, and practical pathways toward broader adoption.

CWH Delivering Value

  • Prioritized service opportunities with the strongest combination of commercial potential and implementation fit.
  • Clarified the economics and conditions for value creation, including approximately $3.5 million in modeled annual incremental gross margin opportunities across clinical investigations and market research.
  • Strengthened technology investment decisions through objective vendor assessments grounded in business, technical, operational, compliance, and adoption requirements.
  • Created an evidence-based foundation for scalable growth, connecting AI investments with commercial objectives, provider-network capabilities, and phased execution.